Introduction
============

Asthma is a disease of airway inflammation and airway hyper-responsiveness[@b1-jaa-5-033] with progressive narrowing of the airways due to both reversible and irreversible functional and structural changes; the apparently irreversible changes in chronic asthma have been denoted as remodeling given that they result in reduction in lung function and vary in terms of the degree of reversibility.[@b2-jaa-5-033] Assessment of airways by high-resolution computerized tomography (CT) of the chest can have a good correlation to the pathological measures of remodeling.[@b3-jaa-5-033] Of late, the forced expiratory volume (FEV~1~) forced vital capacity (FVC) ratio (FEV~1~/FVC) has also been detected as a surrogate marker of remodeling that correlates well with the airway changes assessed by CT scan.[@b4-jaa-5-033] The pathophysiology of asthma inflammation and airway remodeling has been marked by different microstructural changes including abnormal extracellular matrix turnover and fibrosis[@b5-jaa-5-033],[@b6-jaa-5-033] through the participation of an enzyme system called matrix metalloproteinase (MMPs) and its tissue inhibitor.[@b7-jaa-5-033]--[@b9-jaa-5-033] Since modulation of the process by inhibition of MMPs may be beneficial to the asthmatics, we used doxycycline on a long-term basis in an open, prospective, real-world observation. We conducted this pilot work to see the effect of this antibiotic for its additional property of matrix metalloproteinase inhibition[@b10-jaa-5-033]--[@b12-jaa-5-033] and suppression of immunoglobulin-E (IgE)[@b13-jaa-5-033] alongside the use of standard asthma medications.

Methods
=======

Inclusion of patients
---------------------

We selected chronic asthmatics from the outpatient department of the institute who had long standing history of asthma symptoms with documented airflow limitation and significant reversibility (200 mL and 12%) using spirometry in compliance with the American Thoracic Society guideline.[@b14-jaa-5-033] The subjects were incorporated in a real-world observation protocol (approved by the Institutional Ethics Committee) upon signing the written informed consent form to undergo treatment with doxycycline on a long-term basis. Patients younger than 13 years and older than 75 years of age, those unwilling to undergo the study, and those having previous history of doxycycline intolerance or history of exacerbation within the preceding 6 weeks were excluded. Since it was a real world observation, we kept the study in tandem with the practicing style of the physician and the logistics of the real world. All the patients were informed of the need to (a) have repeated spirometry examinations; (b) attend regular follow-up visits; and (c) report the side effects (experienced or suspected), if any, apart from the need to continue doxycycline as an add-on therapy on top of optimal asthma treatments as per the Global Initiative for Asthma guidelines.[@b15-jaa-5-033] All the patients were on inhaled long-acting beta agonists plus inhaled corticosteroids with inhaled reliever short-acting β~2~ agonist prior to randomization so as to stabilize symptoms for at least 6 weeks. Patients were informed about the possible side effects of doxycycline and were instructed to consume the medicine at least 1 hour after eating. The offered dose of doxycycline was 100 mg twice daily and 100 mg once daily for patients with body weight over 40 kg or less than 40 kg, respectively. Ranitidine was co-prescribed universally to lessen the chance of gastrointestinal intolerance. The baseline spirometry data were preserved and the follow up spirometry data were incorporated for statistical analysis as soon as they were available. We looked for changes in both the pre- (initial) and post-bronchodilator values of spirometric variables across the FEV~1~, FVC, ratio of FEV~1~/FVC, and FEF~25--75~ for documentation of improvement, and changes in the FEV~1~/FVC for marking the improvement of remodeling according to the observations outlined by Chae et al.[@b4-jaa-5-033]

Statistical calculations were done on these spirometric variables using two-tailed paired *t*-tests, and significance was noted with a *P*-value \<0.05.

Results
=======

Of the 24 patients being prescribed add-on doxycycline, a total of six patients (three males and three females, mean age of 47.0 ± 14.6 years) were included for data analysis. Their follow-ups were noted during the period from March 15, 2011 to November 03, 2011. Each patient showed an improvement in their asthma symptoms and exhibited reversibility, according to spirometry results. From the rest of the 18 patients, 10 did not perform repeat spirometry before or during the period of data collection. A total of four patients consumed the medicine inconsistently, two had stopped the therapy after a few days, and one had started the drug only recently. In another patient, the drug was stopped for subsequent diagnosis of tuberculosis.

The mean duration of add-on doxycycline between the baseline and posttreatment spirometric assessment was noted as 162.83 ± 83.07 days and the changes in the spirometric variables are displayed in [Table 1](#t1-jaa-5-033){ref-type="table"}. There was a global improvement across all the parameters; however, the change in the post-bronchodilator FEV~1~ was the most significant (*P* = 0.004). The other significant changes noted were post-bronchodilator FVC (*P* = 0.054), and both pre-and post-bronchodilator FEF~25--75~ (*P* = 0.023 and *P* = 0.031, respectively).

When the pre- (baseline) and posttreatment values were plotted on a duration scale, all the variables showed progressive improvement with time. However, the post-bronchodilator values exhibited more significant improvements compared to the pre-bronchodilator values for FEV~1~, FVC, percentage of forced exhaled volume (FEV~1~%), and FEF~25--75~ (displayed in [Figure 1A to D](#f1-jaa-5-033){ref-type="fig"}). No adverse effects of doxycycline were reported by the patients.

Discussion
==========

Asthma is a global problem with a huge health care burden,[@b16-jaa-5-033] and remodeling of asthma is a universal phenomenon. The loss of lung function has been found to be accelerated in asthma despite therapy.[@b17-jaa-5-033],[@b18-jaa-5-033] So far, the treatment of asthma consists essentially of inhaled bronchodilators and inhaled corticosteroids with oral bronchodilators and anti-inflammatory agents used in certain situations as per the recommendation of treatment guidelines.[@b15-jaa-5-033] Asthma therapy has been targeted to achieve symptom 'control' and there has been no option available to treat the accelerated loss of lung function from remodeling.[@b15-jaa-5-033] Clinically, remodeling implies a progressive loss of lung function and reversibility, while pathologically it signifies an array of micro-structural changes that include the deposition and degradation of the extracellular matrix and fibrosis.[@b2-jaa-5-033] Abnormal deposition of the extracellular matrix has been observed in the submucosal and adventitial areas in both the large and small airways.[@b5-jaa-5-033],[@b6-jaa-5-033],[@b19-jaa-5-033],[@b20-jaa-5-033]

Matrix metalloproteinases, a class of Zn-endopeptidase, and their tissue inhibitors (TIMPs) play a very significant role in the process. Several MMPS are found up-regulated in asthma; of these, MMP-9 has been found in higher quantities in the sputum, bronchoalveolar lavage fluid, and serum of asthmatics,[@b7-jaa-5-033]--[@b9-jaa-5-033] and is also found to be elevated in several different situations such as asthma exacerbation,[@b21-jaa-5-033] occupational asthma,[@b22-jaa-5-033] and nocturnal asthma.[@b23-jaa-5-033] Similarly, the tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) has been found to be elevated in asthmatics.[@b7-jaa-5-033] The MMP/ TIMP balance is regarded as important in the development of allergy-induced asthma since it is reduced by the pulmonary administration of TIMP-1 or TIMP-2.[@b24-jaa-5-033] In animal models, different MMP inhibitors are found to reduce airway inflammation[@b24-jaa-5-033] and bronchial hyperreactivity.[@b25-jaa-5-033]

Both early and late reactions in asthma have been found to be reduced in sheep models when MMP inhibitors are used, and thus MMP inhibition may be a prospective therapeutic target in asthmatics.[@b26-jaa-5-033],[@b27-jaa-5-033] We have tried to exploit this concept in a few cases of chronic asthma with the long-term use of a known MMP inhibitor, doxycycline.[@b10-jaa-5-033],[@b11-jaa-5-033],[@b12-jaa-5-033] Such use of doxycycline has been approved by the United States Food and Drug Administration for the treatment of periodontal disease,[@b28-jaa-5-033] and the long-term use of doxycycline has been documented in several other indications with few toxicities noted.[@b29-jaa-5-033]--[@b32-jaa-5-033]

Incidentally, doxycycline is also able to suppress IgE, and this property can also be exploited for the treatment of asthma.[@b13-jaa-5-033] Daoud et al have documented the use of minocycline among people with asthma, and they examined the effects of this drug across a number of spirometric parameters of lung function as related to IgE suppression.[@b33-jaa-5-033],[@b34-jaa-5-033] Doxycycline was found to successfully reduce the airway inflammation and hyper-responsiveness in murine model of Toluene di-isocyanate induced asthma.[@b35-jaa-5-033] Thus, we conclude that doxycycline, by virtue of its MMP inhibitory and IgE suppressive properties, can be a useful adjunct in the management of asthma.

In our observations, we noted significant improvements across measures of obstruction (FEV~1~), and also across the surrogate marker of remodeling FEV~1~/FVC.[@b3-jaa-5-033] The changes in FEF~25--75~ and FEV~1~ suggest that the observed changes took place both in medium and small-sized airways. Given that the improvement exceeded the expected post-bronchodilator value and yet maintaining some reversibility, it suggests some structural changes that may have resulted from the use of the intervention to the benefit of the patients. Such supranormal improvement in the posttreatment spirometry with demonstration of existence of some reversibility suggests the scope of further improvement. Our results clearly exceeded our expectations, and this implies that the so-called remodeling is not necessarily a fixed structural change.

Our observation may be the first of its kind to show a change in the natural history of asthma by pharmacotherapy. Subsequent research should try to address how long this therapy can be continued and how far the natural history of asthma can be changed. It is not possible to speak about the side effects of doxycycline in this observation given that our sample size included a small number of patients. In addition, the chances of gastrointestinal toxicities and the reflux related to the administration of this drug were, perhaps, lessened by the universal use of ranitidine. A good prospective, randomized, double blind study with a much larger sample population might be able to address these questions.

Despite several weaknesses in the current study (ie, small sample size, real-world observation, no control group, no histological proof, and no high-resolution CT assessment of remodeling), our observations warrant attention and further validation.
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###### 

Changes in spirometric variables in response to treatment of add-on doxycycline

                      Before treatment pre-BD   After treatment pre-BD   *P*-value   Before treatment post-BD   After treatment post-BD   *P*-value
  ------------------- ------------------------- ------------------------ ----------- -------------------------- ------------------------- -----------
  FEV~1~ (L)          1.12 ± 0.40               1.38 ± 0.29              0.14        1.30 ± 0.43                1.61 ± 0.34               **0.004**
  FVC (L)             1.97 ± 0.60               2.13 ± 0.49              0.256       2.12 ± 0.63                2.44 ± 0.56               0.054
  FEV~1~%             56.98 ± 11.73             65.13 ± 6.61             **0.028**   61.83 ± 13.33              66.55 ± 6.84              0.227
  FEF~25--75~ (L/s)   0.68 ± 0.29               0.90 ± 0.21              **0.023**   0.86 ± 0.31                1.06 ± 0.23               **0.031**

**Notes:** The table shows the change in the different spirometric variables (FEV~1~, FVC, FEV~1~%, and FEF~25--75~), in terms of both pre- and post-bronchodilator values from treatment of add-on doxycycline. The significant changes (*P* \> 0.05) are marked in bold.

**Abbreviations:** BD, bronchodilator; *P*, probability level; SD, standard deviation; FEV~1~, forced expiratory volume; L, liters; FVC, forced vital capacity; FEV~1~%, percentage of forced expiratory flow; FEF~25--75~ (L/s), patient's exhaled volume (liters per second).
